4 news items
Legend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
LEGN
3 Jun 24
from driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery during this initial period
Legend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA
LEGN
23 May 24
CARVYKTI® infusion. Advise patients to refrain from driving and engaging in hazardous
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
LEGN
22 Apr 24
driving and engaging in hazardous occupations or activities, such as operating heavy or potentially dangerous machinery during this initial period
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
LEGN
5 Apr 24
CARVYKTI® infusion. Advise patients to refrain from driving and engaging in hazardous occupations
- Prev
- 1
- Next